A ntigen-specific immune responses are both initiated and maintained by TCR recognition of Ag peptide assembled within the MHC groove. Selection of the TCR repertoire during thymic development begins with positive selection of T cells expressing receptors with low affinity for self-MHC, and negative selection of the high-affinity cells (1) . Persistence in the peripheral repertoire requires homeostatic division, and this also relies on TCR recognition of self-epitopes (1) . TCR-␣ and -␤ chains are composed of somatically rearranged V, D, and J germline-encoded gene segments (2) , and contain three highly variable complementarity-determining regions (CDRs) 2 that confer Ag specificity. CDR1 and 2 are encoded by germline V segments, whereas CDR3 is created by somatic rearrangement and makes a greater contribution to TCR diversity (2) . Crystallographic analysis of several class-I-restricted and one class-II-restricted TCRs has shown that TCR-␣ has more contacts with peptide than TCR-␤ and is presumably of greater importance in peptide recognition (3) (4) (5) (6) (7) (8) . Specifically, dominance of the TCRAV domain in peptide recognition has been established (4, 6) . Besides, TCR-␣ is also important in making contacts with the ␣-helices of the MHC (9) . In addition to structural analyses, studies of single TCR-transgenic mice and clonal TCR reconstitution systems suggest that recognition of foreign Ags is predominantly dependent on TCR-␣ and that multiple TCR-␤-chains can create the same Ag specificity when paired with a single TCR-␣ during generation of the T cell repertoire (10 -13) .
The melanocyte differentiation Ag Melan-A/MART-1 is a self protein of unknown function expressed by melanocytes and most malignant melanoma cells, but not by other tissues (14, 15) . Among the several melanoma-associated Ags so far identified, it has received particular attention because of its "immunodominance" in patients carrying the HLA-A2 allele: it is recognized by 90% of tumor-infiltrating lymphocytes from HLA-A*0201 patients. This immunodominance is subject to extremely stringent requirements (16) : only two largely overlapping peptides, Melan-A 26 -35 and 27-35, of intermediate affinity for HLA-A*0201 (17, 18) . HLA-A2 tetramers synthesized around the Melan-A A27L peptide analog have been used to identify Melan-A-specific T cells ex vivo among circulating lymphocytes from both melanoma (19 -21) and vitiligo patients (22, 23) . A surprising finding was a large Melan-Aspecific naive T cell pool: up to 70% of HLA-A*0201 healthy donors possess discrete amounts of tetramer-positive cells, free from signs of previous Ag encounter ( [23] [24] [25] [26] [27] . The size of the circulating Melan-A T cell pool in adults is at least 100-fold larger than current estimates for naive Ag-specific lymphocyte precursors, and approaches that of epitope-specific memory CD8 T cells. Sequence homology between the Melan-A peptide and a broad range of self-derived proteins (28, 29) suggests that cross-recognition of many ligands may play an important role in positive thymic selection and generation of a large naive T cell pool. High frequencies of Melan-A-specific T cells among CD8 single-positive (SP) thymocytes from HLA-A2 individuals (27) indicate that a high thymic output makes a major contribution to this precursor frequency.
It is thus of interest to determine whether specific TCR sequence motifs are involved in Melan-A recognition and in positive thymic selection of Melan-A-specific T cells. Previous experiments, confined to TCR-␤, indicated that generation of the large Melan-Aspecific T cell pool was not due to selection of a particular TCR
T cell lines
For the generation of peptide-specific T cell lines, PBMC were monocytedepleted by exclusion of plastic adherent cells. PBMC (10 5 /well) were cultured in complete RPMI medium in the presence of 10 5 peptide-pulsed T2 cells (34) using 1-2 g/ml of Melan-A A27L peptide. Low-dose (25 U/ml) IL-2 was added on day 5. Cells were stimulated at 3-wk intervals.
Peptides and tetramers
The following peptides were purchased from Primm (Milan, Italy): Melan-A 26 -35 (EAAGIGILTV), Melan-A A27L (an analog of the Melan-A 26 -35 epitope carrying a substitution of Ala for Leu at position 2 from the NH2 terminus, ELAGIGILTV) (35), influenza matrix Flu-MA 58 -66 (GILG-FVFTL), and MAGE-3 271-279 (FLWGPRALV). All peptides were Ͼ90% pure as indicated by analytical HPLC. Lyophilized peptides were diluted in DMSO and stored at Ϫ20°C. MHC/peptide tetramers built around the first three peptides were purchased from Beckman-Coulter (iTAg MHC tetramers; San Diego, CA). For some experiments, a mutated A2/Melan-A tetramer, containing the substitution Val for Ala at position 245 known to alter the interaction between class I and CD8 (36, 37) , was used (38) .
Abs and flow cytometry
PBMC were stained with tetramers-PE (0.5 g/10 6 cells) for 15 min at 37°C; after two washes, indirect double-staining was performed on ice using anti-human CD8 mAb (OKT8, IgG2a) and FITC-labeled goat antimouse IgG2a (Southern Biotechnology Associates, Birmingham, AL) as second mAb. The specificity of each tetramer was confirmed by staining CTL lines or clones specific for HLA-A2 in association with the peptide of interest (data not shown). To minimize background staining, tetramers were titrated and used at the lowest concentration that still gave a discernible population. Triple stainings with tetramer-PE, anti-CD45RA-CYC (BD Biosciences), and either anti-CD45RO-FITC (Caltag Laboratories, Burlingame, CA) or anti-CD56-FITC (Southern Biotechnology Associates), were performed to assess the naive/effector/memory phenotype of tetramer ϩ cells. For the TCR repertoire studies, the following Abs (mAbs) were used: anti-AV2 (Beckman-Coulter), anti-AV24 (C15, IgG1), anti-AV12-FITC (Endogen, Woburn, MA), and anti-BV1, -3, -4, -5, -6, -8, -12, -13, -14, -16, -20, -21-FITC (Beckman-Coulter). Cells were analyzed on a FACSCalibur (BD Biosciences).
TCR down-regulation assay
T2 target cells were pulsed for 1.5 h with various concentrations of Melan-A A27L peptide in serum-free medium (X-VIVO 15; BioWhittaker, Walkersville, MD) at 37°C, washed four times, and then added to effector cells to give an E:T ratio of 1:5. After 3 h at 37°C, TCR internalization was measured by flow cytometry using HLA-A2 tetramers synthesized around the Melan-A A27L peptide. The use of the same reagent (A2/Melan-A tetramer) for identification of Ag-specific cells and evaluation of surface TCR expression poses a problem when data are analyzed, since tetramer staining intensity decreases due to TCR down-regulation and a cell may escape detection if its fluorescence intensity drops below the gate established to identify specific cells. Therefore, when Ag concentration is increased, a large proportion of the sample population is "lost" because of its undetectability. For this reason, the use of the percentage decrease of tetramer fluorescence intensity as the sole parameter is inappropriate. Therefore, two parameters where used to calculate the percentage of surface TCR within the tetramer ϩ population: the percentage decrease of tetramer fluorescence intensity and the percentage of tetramer ϩ cells still present within the gate.
Cytotoxicity assay

Sorted tetramer
ϩ cells and peptide-specific T cell lines were assayed for specific lysis against an HLA-matched melanoma cell line (501 mel; a kind gift of L. Rivoltini, Cancer Immunotherapy Unit, Istituto Nazionale Tumori, Milan, Italy) or peptide-pulsed T2 cells, respectively, in a standard 4-h chromium release assay. Briefly, 10 6 target cells were labeled with 200 Ci 51 Cr for either 1.5 h (melanoma cells) or 15 h (T2 cells). T2 cells were pulsed with 3 g/ml Melan-A A27L peptide for 30 min at room temperature. T2 cells pulsed with an HLA-A*0201-restricted, irrelevant peptide (MAGE-3 271-279 ) were used as a negative control at the same concentration as the relevant peptide. A total of 10 3 target cells/well were mixed with appropriate amounts of effector cells to give final E:T ratios ranging between 30:1 and 2:1. After 4 h at 37°C, 25 l supernatant was collected, seeded in Lumaplate 96 solid scintillation plates (Packard Instruments Company, Meriden, CT), and counted in a beta counter. The percentage of specific lysis was calculated as: 100 ϫ (experimental release Ϫ spontaneous release)/(maximum release Ϫ spontaneous release). Spontaneous release was assessed by incubating target cells in the absence of effectors and maximum release was determined in the presence of 1% Nonidet P-40 detergent (BDH Biochemicals, Poole, U.K.).
Amplification and sequencing of TCR transcripts
Total RNA from 10 6 cells from each clone was extracted using EUROZOL (Euroclone). First-strand cDNA was synthesized using oligo(dT) and Moloney murine leukemia virus M-MLV Reverse Transcriptase (Invitrogen, Paisley, U.K.) in 20 l final volume. Aliquots of the cDNA were PCR amplified in parallel with a panel of 32 AV-and 24 BV-specific oligonucleotides in conjunction with one AC-(5Ј-GTTGCTCCAGGCCGCG GCACTGTT-3Ј) and one BC-specific (5Ј-TGCTGACCCCACTGTCGAC CTCCTTCCCATT-3Ј) oligonucleotide. The AV-specific primers were taken from the literature (39, 40) .
The BV-specific primers were as follows: BV1 5Ј-GCACAACAGTTC CCTGACTTGCAC-3Ј, BV2 5Ј-TCATCAACCATGCAAGCCTGACCT-3Ј, BV3 5Ј-GTCTCTAGAGAGAAGAAGGAGCGC-3Ј, BV4 5Ј-TTCCCA TCAGCCGCCCAAACCTAA-3Ј, BV5 5Ј-ATACTTCAGTGAGACACAG AGAAA-3Ј, BV6 5Ј-TCTCAGGTGTGATCCAAATTCGGG-3Ј, BV7 5Ј-CACCTGAATGCCCCAACAGCTCTC-3Ј, BV8 5Ј-ATTTACTTTAACA ACAACGTTCCG-3Ј, BV9 5Ј-TTCCCTGGAGCTTGGTGACTCTGC-3Ј, BV10 5Ј-CTCCAAAAACTCATCCTGTACCTT-3Ј, BV11 5Ј-TCAACA GTCTCCAGAATAAGGACG-3Ј, BV12 5Ј-TGTCACCAGACTGGGAA CCACCAC-3Ј, BV13 5Ј-CACTGCGGTGTACCCAGGATATGA-3Ј, BV14 5Ј-GTCTCTCGAAAAGAGAAGAGGAAT-3Ј, BV15 5Ј-CAGGCACAG GCTAAATTCTCCCTG-3Ј, BV16 5Ј-TGAAAGAGTCTAAACAGGAT GAGT-3Ј, BV17 5Ј-TCCTCTCACTGTGACATCGGCCCA-3Ј, BV18 5Ј-GATGAGTCAGGAATGCCAAAGGAA-3Ј, BV19 5Ј-TCAATGCCCCA AGAACGCACCCTG-3Ј, BV20 5Ј-ATCAGCTCTGAGGTGCCCCAGA AT-3Ј, BV21 5Ј-ATTCACAGTTGCCTAAGGATCGAT-3Ј, BV22 5Ј-GGGCAGAAAGTCGAGTTTCTGGTT-3Ј, BV23 5Ј-TTTTATGAAAAG ATGCAGAGCGAT-3Ј, and BV24 5Ј-AAGTCAAGTCAGGCCCCAAA GCTG-3Ј.
The TCRAV-PCR profile was 2 min at 94°C, 30 cycles at 94°C for 1 min, 60°C for 30 s, 72°C for 30 s followed by a 7-min extension. The TCRBV-PCR profile was 2 min at 94°C, 35 cycles at 94°C for 30 s, 55°C for 20 s, 72°C for 1 min followed by a 7-min extension. PCR amplification products were purified using JetSorb gel extraction kit (Genomed, Bad Oeynhausen, Germany) and directly sequenced with the BigDye Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA) using an internal AC-(5Ј-GTCACTGGATTTAGAGTC-3Ј) and BC-specific (5Ј-TGCTTCTGATGGCTCAA-3Ј) oligonucleotide according to the manufacturer's instructions. Sequences were run on an ABI 377 DNA sequencer (Applied Biosystems). The TCR nomenclature proposed by Arden et al. (41) was adopted.
Results
Strong TCR-␣ chain conservation in Melan-A-specific cell clones
Freshly isolated PBMC from one HLA-A2 vitiligo patient (PSA) were stained with HLA-A2 tetramers synthesized around the Melan-A A27L analog peptide (35) together with an anti-CD8 mAb and analyzed by flow cytometry. As shown in Fig. 1A , the A2/Melan-A tetramer ϩ T cells constituted 0.16% of the CD8 ϩ cells. The CD8 ϩ tetramer ϩ population was isolated by flow cytometry cell sorting. Sorted cells were too few to allow directly Ag specificity testing. They were split into two parts: one was shortly expanded in the presence of PHA for functional studies, the other immediately cloned by limiting dilution. Specificity of the sorted cells was demonstrated through peptide-specific TCR down-regulation experiments and cytotoxicity assays against an HLAmatched melanoma cell line (Fig. 1, B and C) . To analyze the TCR repertoire displayed by the CD8 ϩ A2/Melan-A tetramer ϩ T cells, RNA was extracted from 30 clones and cDNA subjected to RT-PCR using a panel of AV and BV oligonucleotides covering virtually 100% of the TCR-␣␤ repertoire. In line with previously published data concerning the heterogeneity of the Melan-A-specific TCR-␤ repertoire (27, 30 -33) , Melan-A-specific CD8 ϩ T cells from this vitiligo patient were found to rearrange many distinct BV gene segments (Fig. 1D) . In contrast, all clones expressed the same rearranged AV gene segment (AV2, 28 of 28 clones; the AV rearrangement of two clones could not be determined) (Fig.  1E ). Direct sequencing with an internal AC-specific primer was performed to determine the complete TCR-␣ CDR3 region of the Melan-A-specific clones (Fig. 2) . The AV2 segment was always productively rearranged and the CDR3 regions were all different, indicative of a large degree of polyclonality in the specific TCR repertoire. Twenty-two of 28 clones (78%) used the AV2.1 segment, while the remaining six used either AV2.2 (five cases) or AV2.3 (one case); these last six clones also used the same AJ segment (AJ48) and contained an identical CDR3␣ size (16 aa). Two clones (PSA.S.6 and PSA.S.26) possessed only two nucleotide differences in their CDR3 and their amino acids were identical. A total of 11 clones expressed a second rearranged AV segment; this also was productive in four cases, in line with figures reported by others (42, 43) .
Circulating Melan-A-specific cells from a second HLA-A2 patient (SCO) affected by melanoma were similarly analyzed. The percentage of A2/Melan-A tetramer ϩ T cells in this patient and the functional analysis of sorted cells are illustrated in Fig. 3 . The molecular characterization of 21 clones obtained after sorting and cloning of the tetramer ϩ cells confirmed a highly selective usage of AV2 segment in this patient, which contributed to form the expressed Melan-A-specific TCR in 20 of 21 clones (Figs. 3D and  4) . Eight clones expressed a second rearranged AV segment and this was also productive in one case.
Dominant usage of TCRAV2 is widely conserved in the Melan-A-specific peripheral repertoire
To assess whether the selective use of this AV segment is a generalized feature of Melan-A-specific cells, PBMC from 14 HLA-A2 patients (seven with vitiligo and seven with melanoma) were analyzed. PBMC were enriched in CD8 ϩ cells with magnetic beads and stained with A2/Melan-A tetramers in association with an anti-AV2 mAb either directly or, when the number of CD8 ϩ cells was too low, following short expansion in the presence of PHA. It is important to note that the mAb we used is specific for the AV2.1 segment and does not cross-react with AV2.2 or AV2.3 (data not shown). Thus, the number of AV2-expressing cells is underestimated when this reagent is used. The high percentages of AV2.1-expressing cells in the tetramer ϩ population of all our patients (range 50 -87%; mean Ϯ SD, 67 Ϯ 10.9%) was consistent with a highly preferential use of AV2 in forming the Melan-Aspecific TCR (Fig. 5) , whereas AV12-and AV24-expressing cells were always undetectable (Fig. 5B) . No other AV families could be tested due to lack of other commercialized AV-specific Abs. We repeated the same stainings using HLA-A2 tetramers built around the natural 26 -35 peptide, as well as tetramers containing a mutation known to reduce the nonspecific binding between HLA-A2 and CD8 (38) . In both cases, we obtained comparable percentages of tetramer ϩ AV2 ϩ cells (data not shown). HLA-A2 tetramers built around the Flu-MA peptide were also used in conjunction with the AV2.1 mAb to stain these samples. None of the A2/Flu-MA tetramer ϩ cells turned out to be AV2.1 ϩ , indicating that preferential usage of this AV segment is specifically relevant for recognition of the self Ag Melan-A (Fig. 5) .
Consistent with previous data indicating that Melan-A-specific CTL from both melanoma and vitiligo patients frequently show signs of an in vivo Ag encounter (23, 25, 44 ), all patients analyzed in this part of the work contained variable proportions of A2/ Melan-A tetramer ϩ lymphocytes displaying an effector/memory phenotype (between 6 and 59%; mean Ϯ SD, 31.3 Ϯ 17.6%, data not shown). To define whether the predominant use of AV2 by the Melan-A-specific repertoire is defined at the preimmune level or reflects a postimmune selection, we analyzed the Melan-A-specific repertoire by tetramer staining PBMC in seven HLA-A2 healthy subjects. PBMC were enriched in CD8 ϩ cells with magnetic beads and stained with A2/Melan-A tetramers. A detectable population was found in five cases (71%) (Fig. 5) . Virtually all tetramer ϩ cells exhibited a CD45RA ϩ CD56 Ϫ phenotype, indicative of a naive repertoire (data not shown). These data are in agreement with previous reports of high frequencies of circulating Melan-Aspecific CD8 T cells with a bona fide naive phenotype (23) (24) (25) (26) (27) . Once again (Fig. 5 ) a large fraction of tetramer ϩ cells, comparable to that found in the patients, expressed the AV2 segment (range 55-90%; mean Ϯ SD, 73 Ϯ 15.4% of the CD8 ϩ cells).
Requirement of single TCRAV and heterogeneous TCRBV segments for Melan-A recognition during expansion of Ag-specific cell lines
Next, peptide-specific cell lines were established from the PBMC of two vitiligo, two melanoma, and one healthy subjects. In all cases, enrichment of tetramer ϩ cells upon two rounds of stimulation correlated with similar expansion rates of AV2.1 cells (Fig. 6A for one representative case) as well as with enhanced TCR downregulation upon peptide engagement (Fig. 6B) and enhanced peptide-specific cytotoxicity (Fig. 6C) . The percentage of AV12 cells increased only slightly or not at all during stimulation (Fig. 6A) . At the highest expansion levels, virtually all tetramer ϩ cells in the peptide-specific lines were AV2.1 ϩ (Fig. 6A) , whereas their BV repertoire as assessed by the use of mAbs specific for 12 BV segments was still highly heterogeneous (Fig. 6D ). These experiments demonstrate that AV2 has a predominant role in determining Melan-A-recognition and that the same Ag specificity can be created by pairing of a conserved TCR-␣ chain with multiple TCR-␤ chains. In addition, they rule out the possibility that A2/Melan-A tetramers cross-react with AV2-containing TCR, irrespective of their Ag specificity.
TCR-␣ dominates in shaping the intrathymic Melan-A-specific repertoire
The origin of the AV2 ϩ , Melan-A-specific T cells, was directly investigated by tetramer staining T cells from the human thymus. High percentages of A2/Melan-A-, but not influenza-specific, cells are detected in the pool of CD8 SP, but not double-positive thymocytes (27) . SP thymocytes constituted 1-5% of thymocytes that were rescued by TCR engagement and matured to express either CD4 or CD8. CD8 SP cells were enriched from the thymus of three HLA-A2 ϩ and three HLA-A2 Ϫ individuals through magnetic depletion of CD4-expressing cells. Staining detected significant numbers of A2/Melan-A tetramer ϩ cells in all three HLA-A2 ϩ cases (mean Ϯ SD, 0.05 Ϯ 0.006%; Fig. 7A ), but in none of the HLA-A2 Ϫ samples (data not shown). A2/Flu-MA tetramer ϩ cells were never detected (Fig. 7B) . Interestingly, most of the A2/Melan-A tetramer ϩ thymocytes expressed AV2.1 (mean Ϯ SD, 78 Ϯ 20.2%) (Fig. 7, A and C) , but neither AV12 ϩ nor AV24 ϩ (Fig.  7C) . Altogether, these results indicate that the preferential usage of AV2 in forming the Melan-A-specific TCR is mostly imposed by intrathymic-positive selection.
Discussion
The data reported in this study show that TCR-␣ is dominant in formation of the TCR repertoire specific for the human self Ag Melan-A/MART-1 and support the view that Ag recognition is mediated predominantly by TCR-␣. The most substantial preservation of TCR-␣ structure was the strongly preferential use of a particular AV segment, whereas the CDR3 regions were less conserved. In fact, crystallography of the TCR-␣␤/peptide-MHC complex has revealed that the CDR1, CDR2, and CDR3 ␣␤ regions generally contribute to the buried surface area in the interface. However, dominance of the AV-encoded CDR1 and CDR2 domains in peptide recognition has since been established. This is exemplified by the D10 TCR, where 23 of 27 atomic contacts with the peptide involved AV and only four involved BV (6). This dominance had not been appreciated previously, although a generalized complex orientation mediated by the AV domain had been proposed (2) . This is consistent with our results concerning recognition of a human self Ag and those of Yokosuka et al. (13) regarding recognition of foreign Ags. In single TCR transgenic mice models, those authors observed that a single TCR-␣ chain generates the same functional Ag specificity when paired to different TCR-␤ chains. Analogously, when we used Melan-A peptides to in vitro stimulate PBMC from various HLA-A2 patients, we observed that AV2-expressing cells were selectively enriched, whereas TCR-␤ chains remained highly polyclonal.
The high precursor frequency of naive Melan-A-specific cells provided a unique situation for assessment of the structural relationship between TCR and peptide/MHC ligand at the preimmune level. The number of Melan-A-specific cells entering the peripheral repertoire is exceptionally high, although many self mimics can contribute to this large precursor population predominantly determined by a high thymic output (27) . The composition of selfpeptide ligands in the thymus is critical in shaping the preimmune T cell repertoire, but is Melan-A expressed and processed intrathymically? There are divergent opinions regarding this question. It was demonstrated that the immunoproteosome does not process the Melan-A 26 -35 peptide (45) , but the standard proteosome should also be expressed by thymic dendritic cells. If Melan-A peptides are processed in the thymus, as negatively selecting ligands they would narrow the structural diversity of self-specific TCR. Interestingly, the preferential use of a highly selected AV segment, as we observed for Melan-A-specific cells, has been reported as a feature of the "tolerant" repertoire (46) . This raises the question of whether AV2 is one of the few segments capable of conferring Melan-A specificity to a TCR, or one of the few AV segments determining a low enough TCR affinity for Melan-A to allow positive selection. In any case, from our data the intrathymic generation of the large Melan-A-specific T cell pool appears to be favored by the selection of a particular TCR. Preferential use of AV2 by Melan-A-specific T cells has been occasionally documented in HLA-A2 melanoma patients. Impressive dominance of this segment in forming the Melan-A-specific TCR was shown in one report where six of nine CTL clones obtained from five patients expressed TCRAV2.1 (47) . However, TCRBV-restricted usage was also noted and practically all subsequent studies regarding the Melan-A-specific T cell repertoire have concentrated their attention on the TCR-␤ alone (30 -33, 48, 49) , presumably due to both technical reasons, i.e., lack of a large panel of AV-specific mAbs, and the persistent assumption that TCR-␤ is the main contributor to peptide recognition despite its recent rebuttal by crystallography. The only exception is one paper in which the clonally expanded Melan-A-specific TCR repertoire was monitored in a melanoma patient during immunization with melanoma-associated peptides (50); AV2-expressing cells were not detected among the clonally expanded populations. However, this patient already displayed a single monoclonal TCR-␣ transcript before immunization and all the repertoire studies were focused on clonally expanded cells, while in our case the AV2-expressing lymphocytes were mainly polyclonal even upon peptide-specific stimulation in vitro. A certain degree of heterogeneity among donors must also be taken in consideration. Our data suggest that AV2-containing TCRs are not the only ones involved in Melan-A recognition, and a few clones expressing other AV segments have been described (Ref. 51 and clone SCO126). Rather, it would seem more likely that AV2-containing TCRs have either a structural or a functional advantage during intrathymic-positive selection and peripheral expansion.
The immunodominance of Melan-A/MART-1 Ag in association with HLA-A2 has received particular attention from the immunotherapeutic standpoint, since this HLA allele is predominant in the North American Caucasian population and Melan-A reactivity is frequent in tumor-infiltrating lymphocytes from HLA-A2 melanoma patients. A specific allele/ligand combination, whose minimal terms are HLA-A*0201 and a single conserved glycine in position 5 shared by Melan-A peptides as well as by the large number of Melan-A epitope mimics so far described (29) , has been proposed as the major contributor to this immunodominance (16) . Our data now indicate that an additional structural constraint is imposed on the TCR for engagement with Melan-A peptides presented by HLA-A2. We would thus like to extend this previous observation by proposing that a unique allele/ligand/TCR-␣ combination, which includes TCRAV2, may be the molecular basis for Melan-A immunodominance.
In the light of our findings, the important role of TCR-␣ in determining Ag specificity, structurally suggested by crystallography, but functionally limited to "artificial" models, is now demonstrated for the first time in the case of a natural Ag response in humans and could represent the general molecular basis for recognition of both self and non-self Ags.
